IDO1 and neoplasm: The GBM immunosuppressive TME is driven by tumor-intrinsic factors and brain tissue responses to tumor antigens, such as overexpression of the indoleamine 2,3-dioxygenase (IDO) enzyme [37] and the oncogene transforming growth factor beta (TGF-β) [38,39].